Description
The IDKmonitor® Infliximab free ADA ELISA measures free antibodies against Infliximab.
It is thought that ADA functionally neutralise the therapeutic antibodies or induce their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFa antibody application. Regular monitoring of both the drug level and the formation of antibodies against the drug is important for optimising therapy and the associated long-term therapeutic success.
